Recursion Pharmaceuticals (RXRX) Income from Continuing Operations (2020 - 2026)
Recursion Pharmaceuticals posted quarterly Income from Continuing Operations of 117504000.0 for Q1 2026, up 41.97% year-on-year from 82767010.29 in Q1 2025, and down 8.68% on a QoQ basis from 108122000.0 in Q4 2025.
Recursion Pharmaceuticals (RXRX) has 7 years of Income from Continuing Operations data on file, last reported at 117504000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 41.97% year-over-year to 117504000.0; the trailing twelve-month figure through Mar 2026 stood at 559776000.0 (up 2.61% YoY), and the FY2025 full-year result was 644759000.0, down 39.06% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 117504000.0, down from 108122000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 55981000.0 in Q1 2022 and bottomed at 202487000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 93017000.0 (2023), against an average of 105865705.88.
- The widest annual swing landed in 2025, when Income from Continuing Operations plunged 121.6%; it then soared 41.97% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 60982000.0 in 2022, then tumbled by 52.5% to 92996000.0 in 2023, then slumped by 92.38% to 178906000.0 in 2024, then surged by 39.56% to 108122000.0 in 2025, then dropped by 8.68% to 117504000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 117504000.0 (Q1 2026), 108122000.0 (Q4 2025), and 162253000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Recursion Pharmaceuticals | 2.01 Bn | 1.35 Bn | -6.02 Mn | -117.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -117.50 Mn |
| Dec 31, 2025 | -108.12 Mn |
| Sep 30, 2025 | -162.25 Mn |
| Jun 30, 2025 | -171.90 Mn |
| Mar 31, 2025 | -202.49 Mn |
| Dec 31, 2024 | -178.91 Mn |
| Sep 30, 2024 | -95.84 Mn |
| Jun 30, 2024 | -97.54 Mn |
| Mar 31, 2024 | -91.37 Mn |
| Dec 31, 2023 | -93.00 Mn |
| Sep 30, 2023 | -93.02 Mn |
| Jun 30, 2023 | -76.73 Mn |
| Mar 31, 2023 | -65.33 Mn |
| Dec 31, 2022 | -60.98 Mn |
| Sep 30, 2022 | -62.57 Mn |
| Jun 30, 2022 | -66.19 Mn |
| Mar 31, 2022 | -55.98 Mn |
| Dec 31, 2021 | -64.96 Mn |
| Sep 30, 2021 | -46.40 Mn |
| Jun 30, 2021 | -40.93 Mn |
| Mar 31, 2021 | -30.48 Mn |
| Dec 31, 2020 | -25.58 Mn |
| Sep 30, 2020 | -22.47 Mn |
| Jun 30, 2020 | -18.22 Mn |
| Mar 31, 2020 | -18.34 Mn |